Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2011; 17(8): 1045-1050
Published online Feb 28, 2011. doi: 10.3748/wjg.v17.i8.1045
Published online Feb 28, 2011. doi: 10.3748/wjg.v17.i8.1045
Table 1 Tumor size
| Pre-treatment | Post-treatment | Ratio | |
| Sorafenib 1 | 69.4 | 159.0 | 2.3 |
| Sorafenib 2 | 58.6 | 165.3 | 2.8 |
| Sorafenib 3 | 109.0 | 150.9 | 1.4 |
| Sorafenib 4 | 192.9 | 547.2 | 2.8 |
| Control 1 | 49.0 | 210.3 | 4.3 |
| Control 2 | 24.5 | 240.0 | 9.8 |
| Control 3 | 78.8 | 246.1 | 3.1 |
| Control 4 | 30.6 | 436.6 | 14.0 |
Table 2 Time intensity curve
| Variation | |||||||
| V0 | VImax | TPI | PI | PI | TPI | ||
| SonoVue | |||||||
| Sorafenib 1 | 0W | -44.8 | -22.3 | 1.00 | 24.5 | ||
| 2W | -48.3 | -13.6 | 3.40 | 34.7 | 1.4 | 3.4 | |
| Sorafenib 2 | 0W | -45.5 | -19.6 | 0.27 | 25.8 | ||
| 2W | -48.4 | -35.3 | 0.87 | 13.1 | 0.51 | 3.2 | |
| Sorafenib 3 | 0W | -49.6 | -43.7 | 1.00 | 5.9 | ||
| 2W | -49.1 | -16.8 | 1.13 | 32.3 | 5.5 | 1.1 | |
| Sorafenib 4 | 0W | -39.6 | -14.9 | 0.86 | 24.7 | ||
| 2W | -45.6 | -18.8 | 4.14 | 26.8 | 1.1 | 4.8 | |
| Control 1 | 0W | -46.4 | -25.0 | 2.00 | 21.5 | ||
| 2W | -45.3 | -8.7 | 1.13 | 36.6 | 1.7 | 0.57 | |
| Control 2 | 0W | -48.5 | -14.6 | 2.53 | 34.0 | ||
| 2W | -47.8 | -16.0 | 2.60 | 31.8 | 0.94 | 1.0 | |
| Control 3 | 0W | -46.9 | -12.4 | 2.07 | 34.4 | ||
| 2W | -49.0 | -18.1 | 2.93 | 30.9 | 0.90 | 1.4 | |
| Control 4 | 0W | -49.9 | -37.2 | 1.06 | 12.7 | ||
| 2W | -50.0 | -28.5 | 1.47 | 21.5 | 1.7 | 1.4 | |
| Sonazoid | |||||||
| Sorafenib 1 | 0W | -49.1 | -21.9 | 2.27 | 27.2 | ||
| 2W | -48.1 | -13.5 | 3.67 | 34.5 | 1.3 | 1.6 | |
| Sorafenib 2 | 0W | -47.8 | -21.4 | 1.00 | 26.3 | ||
| 2W | -49.7 | -19.0 | 2.13 | 30.7 | 1.2 | 2.1 | |
| Sorafenib 3 | 0W | -34.5 | -19.1 | 2.60 | 15.4 | ||
| 2W | -47.9 | -10.0 | 2.67 | 37.9 | 2.5 | 1.0 | |
| Sorafenib 4 | 0W | -35.8 | -13.0 | 1.33 | 22.8 | ||
| 2W | -41.8 | -9.5 | 4.20 | 32.3 | 1.4 | 3.2 | |
| Control 1 | 0W | -42.5 | -16.2 | 2.33 | 26.3 | ||
| 2W | -48.6 | -13.0 | 2.80 | 35.6 | 1.4 | 1.2 | |
| Control 2 | 0W | -37.8 | -7.4 | 4.27 | 30.4 | ||
| 2W | -44.0 | -12.8 | 1.80 | 31.2 | 1.0 | 0.42 | |
| Control 3 | 0W | -41.7 | -14.7 | 1.60 | 27.0 | ||
| 2W | -49.2 | -18.0 | 2.14 | 31.2 | 1.2 | 1.3 | |
| Control 4 | 0W | -46.7 | -27.7 | 2.87 | 18.9 | ||
| 2W | -49.8 | -23.7 | 1.60 | 26.1 | 1.4 | 0.56 | |
- Citation: Yoshida K, Hirokawa T, Moriyasu F, Liu L, Liu GJ, Yamada M, Imai Y. Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: A pilot study. World J Gastroenterol 2011; 17(8): 1045-1050
- URL: https://www.wjgnet.com/1007-9327/full/v17/i8/1045.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i8.1045